Valneva SE is a specialty vaccine company headquartered in Saint-Herblain, France, focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases with signific... Valneva SE is a specialty vaccine company headquartered in Saint-Herblain, France, focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs. It markets three proprietary vaccines: Ixiaro against Japanese encephalitis, Dukoral for cholera and traveler's diarrhea, and IXCHIQ, the world's first single-dose chikungunya vaccine approved in multiple regions. Valneva's pipeline features the leading Lyme disease candidate VLA15 in Phase 3 trials, partnered exclusively with Pfizer, alongside programs for Shigella, Zika, and others, leveraging expertise across vaccine platforms. With manufacturing sites in Scotland, Sweden, and Austria, and over 700 employees across six countries, the company generated approximately €170 million in vaccine sales in 2024, primarily from North America. Valneva emphasizes innovation for global public health threats, targeting cash-flow positivity and profitability by 2027 through commercial growth and R&D advancements. Its vision drives universal access to prevent vaccine-preventable diseases while prioritizing sustainability and ethics.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

Climate Targets data not yet covered for Valneva

We have not yet reviewed Valneva's disclosures for Climate Targets data.

If this data is relevant to your work, you can submit a data coverage request and our team will investigate the company's disclosures and capture the data if available.

Would you like us to review Valneva's data?

Start your 30-day free trial to request a data review for Valneva.

Start Free Trial

Legal Center Contact Us